There is increasing interest in periprostatic fat and its influence on prostate cancer aggressiveness. In vitro data suggest that adipose stromal/stem cells (ASCs) can increase production of cytokines and growth factors resulting in invasive growth and metastasis in prostate cancer. The objective of the study was to determine the interaction between 5a-reductase inhibitors (5ARIs) and periprostatic adipose tissue (PPAT) and factors of prostate cancer aggressiveness. In this retrospective study, we identified 61 patients treated with 5ARIs for a period of ≥12 months before undergoing radiation therapy (brachytherapy or external beam radiotherapy). The control group consisted of 117 patients without any exposure to 5ARIs. Prior to being treated, all patients underwent abdominal computed tomography (CT). To measure PPAT, we defined the fat pad anteriorly to the prostate, as well as the intra-abdominal visceral adipose tissue (VAT) and subcutaneous tissue (SAT) at the level of L4/L5. All contours were performed manually. These adipose tissue measurements were correlated with the Cancer of the Prostate Risk Assessment (CAPRA) score using Pearson correlation coefficient. Differences in fat contents were evaluated using Student's t-test. Median time on 5ARIs for the 61 patients was 12 months (range 12-96). Patient on 5ARIs had a significantly (p < 0.001) smaller PPAT (0.4, SD 0.5) than patients without a 5ARI (0.6 cc, SD 0.4). There was no significant correlation between the CAPRA score and fat measurements when adjusted for 5ARI use (p = 0.18). In non-5ARI users, BMI was not correlated with PPAT but was correlated with SAT and VAT volume and its density. There were no significant differences in diabetics (p = 0.3), metformin users (p = 0.4) or statin users (p = 0.09) between both groups. 5ARIs taken for at least 12 months induce changes in PPAT volume. Whether these changes or the extent of changes will have an influence on outcome remains unknown.
INTRODUCTION
The interaction between obesity and prostate cancer is only poorly understood (De Pergola & Silvestris, 2013; Dobbins et al., 2013) . In previous studies, we found that visceral adipose tissue (VAT) (Xia et al., 2014) , subcutaneous adipose tissue (SAT) and waist circumference were associated with more aggressive pathological features in prostate cancer (Zilli et al., 2010) , but SAT had no prognostic significance after external beam radiotherapy (EBRT) in intermediate risk cancers (Zilli et al., 2011) . Others have studied the influence of adipose tissue distribution in prostate cancer and found that a larger volume of SAT was independently associated with overall survival in metastatic castration-resistant prostate cancer patients (Antoun et al., 2015) but not after curative prostatectomy (Ohwaki et al., 2015a) .
Mechanisms through which adipose tissue could interact with cancer can be explained by a hyper-inflammatory state (9-12), mitogenic and anti-apoptotic activities as well as mild chronic suppression of the immune system (Louie et al., 2013) and several other circulating factors potentially associated with cancer (Byers & Sedjo, 2011) . Testosterone is implicated in both benign or malignant prostate disease and changes in fat metabolism. An interesting setting to study is the interaction of prostate cancer with fat metabolism and testosterone, and the effect of 5a-reductase inhibitors (5ARIs) on both the prostate and body fat. 5ARIs drugs (dutasteride and finasteride) inhibit the enzyme that converts testosterone to dihydrotestosterone (DHT) intracellularly. There are two isoenzymes, the SRD5A1 and the SRD5A2. Both are overexpressed in benign and malignant prostate tissue and both are inhibited by the drug dutasteride, and the SRD5A2 isoenzyme by the drug finasteride (Keam & Scott, 2008) . Obesity has been shown to influence increases in 5a-reductase type 2 gene promoter methylation (Bechis et al., 2015) . Dutasteride has especially been shown to increase hepatic insulin resistance and increase rates of de novo lipogenesis and decrease adipose tissue lipid mobilization (Hazlehurst et al., 2016) .
Therefore, the study of periprostatic adipose tissue (PPAT), its influence on prostate cancer and the influence of 5ARIs on PPAT can help to elucidate this complex interaction between testosterone, fat metabolism and prostate cancer. In vitro data suggest that adipose stromal/stem cells (ASCs) can increase production of cytokines and growth factors resulting in invasive growth and metastasis in prostate cancer (Strong et al., 2015) , and that gene expressions of genes involving adipogenic/anti-lipolytic, proliferative/anti-apoptotic and mild immunoinflammatory processes in PPAT differs in lean compared to obese patients (Ribeiro et al., 2012a) . In vitro there is an influence of prostate cancer cells on the PPAT to produce factors that promote aggressiveness (Ribeiro et al., 2012b) . Interleukin-6 in the PPAT has been shown to more than 100-fold higher than in the serum. An association between IL-6 levels in the PPAT and high grade prostate cancer has been found but no such association for IL-6 levels in the serum and high grade cancer (Finley et al., 2009 ).
Measurements of PPAT on different imaging modalities and its influence on prostate cancer have not been extensively studied. Previous studies measured the PPAT volume only rudimentarily as either a perpendicular diameter of the anterior fat pad on transrectal ultrasound (Bhindi et al., 2012) or on magnetic resonance imaging (MRI) as the distance from the pubic symphysis to the prostate gland (Woo et al., 2015) .
In this present study, we investigated the interaction between 5ARIs and the adipose tissue at the level of the prostate as manually delineated on computed tomography (CT).
MATERIALS AND METHODS
This study received approval from the institutional research ethics board. Patients were included without consideration of cancer characteristics such as Gleason score, prostate-specific antigen (PSA), body mass index (kg/m 2 ) or age. The only inclusion criterion was having a CT scan for treatment planning purposes. From the 101 patients in our institutional database who were treated with at least 12 months of 5ARIs before the scan, we analyzed the last 61 consecutively treated patients between March 2009 and January 2016. Because 5ARIs are often given for low-risk cancers on active surveillance or for urinary problems in the absence of prostate cancer, patients on 5ARIs had mostly low-risk or lower tier intermediate risk cancers and were predominantly treated with permanent seed prostate brachytherapy. A cohort of 117 patients was randomly selected among patients treated in the same time frame and with available CT scan served as the control group. As our university center is a referral site for prostate brachytherapy, the control group consisted of patients treated predominantly with high-dose rate brachytherapy.
Measurements
Height and weight were measured for each patient before treatment. BMI (kg/m 2 ) was calculated and categorized into three categories: normal weight (<25 kg/m 2 ), overweight (25-29 kg/m 2 ) and obese (≥30 kg/m 2 ) according to the National Institutes of Health classification.
Contouring
All contouring was performed manually by a single person blinded to patients' characteristics using the Eclipse Treatment Planning System (Varian Medical Systems, Palo Alto, CA, USA) version 13.
First, VAT and SAT were contoured on CT scan at the level of intervertebral space L4 and L5. As the adipose tissue around the prostate is difficult to distinguish from the surrounding tissues, we defined the fat pad anteriorly to the prostate only at the caudal end where the branches of the pubic bone meet and called it PPAT.
This being a retrospective study and most patients on a 5ARI were treated with brachytherapy, the scan did not reach the level of L4/5 in most patients. We therefore excluded these patients from analysis of SAT and VAT tissue and included only the 113 patients with scan reaching L4/5 and having had no treatment with a 5ARI.
CT thickness depended on the scanning protocol utilized and was set at 1, 1.5 or 3 mm. To be able to compare volume data, fat was contoured on 1-3 slices to achieve a minimum of 3-mm thickness for all patients. Data on fat tissue density on CT were calculated as mean radiodensity in Hounsfield units (HU) AE standard deviation.
Statistical analysis
Differences between groups were analyzed using chi-square test for categorical variables. Skewedness of the distribution of PPAT volume, density and the standard deviation of density were tested with the Kolmogorov-Smirnov. All three were skewed, log-transformed and compared using Student's t-test. Correlations between BMI and fat measurements were analyzed with the Pearson correlation coefficient. Logistic multivariate regression analysis was used to analyze factors predicting for PPAT volume.
The Cancer of the Prostate Risk Assessment (CAPRA) score was calculated as a composite score to summarize prostate cancer aggressiveness. The CAPRA has been shown to predict stage, recurrent bone metastases, cancer-specific mortality and allcause mortality (Cooperberg et al., 2009) . Analysis was performed using SPSS 17.0 for WINDOWS (IBM SPSS, Chicago, IL, USA).
RESULTS
Median time on 5ARIs for the 61 patients was 12 months (range 12-96). There was no difference in age (p = 0.4) or BMI (p = 0.2), whether overweight (>25 kg/m 2 , p = 0.6) or obese (>30 kg/m 2 , p = 0.3) between patients on 5ARIs and patients in the control group. Most patients on 5ARIs were treated with seed brachytherapy (97%) vs. only 2% in the control group. Therefore, patients with 5ARIs had lower Gleason scores, number of positive biopsies and PSA values ( Table 1 ). The 5ARIs group had significantly lower CAPRA scores (median = 2, IQR 2-3) than non-users (median = 5, IQR 4-6, p < 0.001 Mann-Whitney nonparametric test). There was weak significant correlation between the CAPRA score and the PPAT volume (r = 023, p = 0.003). But on separate multivariate linear regression analysis adjusted for 5ARIs use, PPAT was not predictive of the total CAPRA score anymore (p = 0.18).
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Patient on 5ARIs had a significantly smaller PPAT ( Fig. 1 and Table 2 ) than patients without a 5ARI.
BMI was not correlated with PPAT but with VAT and SAT volume and its density (Table 3) .
There were no significant differences in diabetic patients, statin users or in diabetic vs. non-diabetic patients between both groups (detailed data not shown, p > 0.09). In multivariate analysis, only 5ARI use but not BMI or statin use did predict for PPAT volume (Table 4) . After a median follow-up of 18 months (IQR 8-36), so far only one patient experienced biochemical recurrence.
DISCUSSION
In this study, we showed that patients treated with at least 12 months of a 5ARIs had significantly smaller PPAT. Additionally, we found that PPAT is independent of BMI, compared to the volume and density of VAT and SAT which were correlated with BMI. This is contrary to our previous publication (Tiberi et al., 2014) , where our group was able to show a weak correlation between BMI, VAT, SAT and PPAT. This could be because of the fact that the PPAT was defined differently in this study. In our previous study, we defined the PPAT as the fat anteriorly and not posteriorly and laterally to the prostate and excluded the tissue medial to the levator ani muscles. The definition of the lateral adipose tissue was dependent on the operator and the position of the levator ani muscle as well as rectal filling. In this present study, only the fat anteriorly to the prostate was included.
Because of the short median follow-up of 18 months, small patients number and presence of predominantly low-risk cancer features, we are unable to analyze the influence of the PPAT on recurrence of disease. Nevertheless, this present analysis can stimulate further interest into the interaction between 5ARIs, fat distribution and prostate cancer.
In this study as well as in our previous study, we could not find any correlation between fat measurements (neither periprostatic nor VAT/SAT) and prostate cancer aggressiveness as measured using the CAPRA score. This is surprising, given that Ohwaki et al. (2015b) found that when stratified by the median VAT, patients with a higher BMI had a higher Gleason score. Antoun et al. (2015) found that a higher volume of SAT was associated with better overall survival in metastatic castration-resistant prostate cancer. SRD5A1 is expressed within adipocytes (Wake et al., 2007) , and a direct effect on adipose tissue has been shown with the use of 5ARIs. A 3-month treatment with dutasteride but not finasteride has been shown to increase body fat and induce changes consistent with impaired insulin sensitivity in adipose tissue (Upreti et al., 2014) . It would be interesting to separate further studies according to which isoforms of 5ARIs are being medically inhibited. Because of the relatively small number of patients in our study, we did not further subdivide the present cohort in order not to weaken the analysis.
In one randomized trial, testosterone replacement therapy together with finasteride increased fat-free mass and reduced fat mass in older hypogonadal men compared to testosterone alone (Borst et al., 2014) . No such effect was seen in a different trial (Bhasin et al., 2012) . They have been shown to decrease proton density fat fraction on magnetic resonance spectroscopy of the liver (Hazlehurst et al., 2016) .
While other groups measured PPAT only as the diameter of the anterior fat pad with either transrectal ultrasound or MRI (Bhindi et al., 2012; Woo et al., 2015) , our group used CT to define PPAT manually which is a more precise technique. The development of guidelines on how to measure PPAT on CT or MRI is important in future studies on the subject.
CT measurement of adipose tissue does not only give quantitative information, but can also give qualitative information. In a Framingham Heart Study, CT substudy, each decrease in 1 SD in VAT HU was associated with an increase in cardiometabolic risk factors (Rosenquist et al., 2013) . We did not find that fat tissue density was correlated with prostate cancer aggressiveness or cardiovascular risk factors such as diabetes or hypercholesterolemia. Whether the observed changes in 5ARIs users in SAT density are clinically relevant (mean difference of 6.5 HU) is doubtful.
A drawback of our study is the lack of validation of the contouring. We are presently developing software to automatically determine fatty tissue more consistently. One could therefore argue that a mean difference in PPAT of 0.2 cc between both groups is negligible or because of contouring variation. But we believe that these differences are real because PPAT was contoured after considerably zooming in on the scanner to the area of interest.
Another weakness is the lack of comparison of adipose tissue measurements before and after the treatment with a 5ARI. Furthermore, 5ARI-induced changes in PPAT could depend on prostate cancer characteristics. As most patients on a 5ARI had low-risk cancers, such an effect could not be measured.
The interaction between PPAT and the prostate has been shown previously to probably be influenced by the secretion of hormones and cytokines (Toren & Venkateswaran, 2014) . Cytokines synthesized by fat-resident regulatory and conventional T cells could directly affect the synthesis of inflammatory mediators. It has also been shown that regulatory T cells (10) produce leptin and high amounts of their receptors, both associated with adipose tissue mass (De Rosa et al., 2007; Ghantous et al., 2015) . These mechanisms offer a potential target for the treatment of prostate cancer and prostate benign diseases.
Furthermore, there are BMI-increasing alleles that are associated with, among others, increased subcutaneous fat and higher adiponectin levels (10). In addition, Finley et al. (2009) showed that circulating IL-6 levels were not correlated with IL-6 levels in PPAT. Interestingly, IL-6 levels in PPAT but not in the serum were correlated with higher Gleason scores. IL-6 can activate the androgen receptor and may promote intracellular synthesis of androgens in the prostate (Culig & Puhr, 2012) . 5ARIs could counteract such an effect. Ribeiro et al. (2012a) showed that gene expression in PPAT could influence prostate cancer through different gene expressions in obese patients compared to leaner ones. These observations suggest that the anti-inflammatory properties of some immune cells (10) to inhibit elements of the metabolic syndrome may have therapeutic potential in prostate cancer. Furthermore, our data show the existence of a direct link between PPAT in leaner patients and prostate cancer aggressiveness, which is one step closer to personalizing prostate cancer treatment.
CONCLUSION
We found that 5ARIs appear to affect PPAT volume. The effects of these changes on cytokines, adipokines and prognosis are subject to future investigations which may help to further elucidate the interaction between obesity, gene methylation, insulin resistance and systemic inflammation. The knowledge of these mechanisms harbors several potential targets for prostate cancer and benign disease.
